Werewolf Reports WTX-124 Response Rates Up to 37.5% and FDA-Aligned Phase 2 Dose
HOWL has more than doubled off its 52-week low of $0.27.
Summary
New SITC data showed WTX-124 combination response rates of 37.5% in NSCLC and 15.8% in melanoma, plus an FDA-aligned 18 mg Phase 2 dose; WTX-330 also showed activity, including a confirmed partial response in gallbladder cancer.
Key Events · Product Development and Regulatory · HOWL
-
WTX-124 Combination Response Rates Disclosed
In dose expansion with pembrolizumab, WTX-124 produced a 37.5% response rate in NSCLC patients with prior chemoimmunotherapy, 15.8% in cutaneous melanoma patients with prior ICI and targeted therapy, and 33% in non-primary ICI-resistant disease.
-
FDA Aligns on 18 mg Phase 2 Dose
Werewolf aligned with the FDA on a WTX-124 recommended Phase 2 dose of 18 mg IV Q2W for both monotherapy and combination with pembrolizumab, administered safely in the outpatient setting.
-
WTX-330 Shows Monotherapy Activity
Across 24 patients, WTX-330 produced a confirmed partial response in gallbladder cancer and intratumoral IL-12/STAT4 signaling in 7 of 9 paired biopsies, with treatment-related adverse events dramatically reduced versus first-in-human material.
-
Development Funding Not Committed
The company said it 'continues to explore opportunities' for further clinical development of WTX-124 and WTX-330, with no new trial funding announced.
Analysis · HOWL · Life Sciences
New clinical data on both of Werewolf's remaining clinical programs landed at SITC. In combination with pembrolizumab, WTX-124 produced a 37.5% response rate in NSCLC patients with prior chemoimmunotherapy and 15.8% in cutaneous melanoma patients with prior ICI and targeted therapy; the company has also aligned with the FDA on an 18 mg IV Q2W recommended Phase 2 dose for both monotherapy and combination use. WTX-330, meanwhile, showed a confirmed partial response in a gallbladder cancer patient and evidence of intratumoral IL-12/STAT4 signaling in 7 of 9 paired biopsies. Why it matters: these are the clinical foundation for whatever value the programs carry into the pending reverse merger with Ambros Therapeutics, disclosed on 2026-08-21 and now before shareholders via the amended S-4 filed 2026-10-26. Against a going-concern warning and a $22 million cash balance reported in the last 10-Q, the company says it 'continues to explore opportunities' for further development rather than committing to fund the next trials itself.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HOWL was trading at $1.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.1M. The 52-week trading range was $0.27 to $1.27. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.